
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
Recent investor discussions regarding Oxford Biomedica Plc (OXB) show a mix of optimism and caution among shareholders. Over the past weeks, OXB's stock has been noted for its solid performance, having risen from approximately 170p over the last year and a half. Investors holding shares in tax-advantaged accounts have expressed intentions to sell for profits before potentially rebuying after a price dip, indicating some speculative sentiment. One user remarked, "Becoming a preferred vector manufacturer for a giant like BMS is great," reflecting a positive outlook on OXB's strategic partnerships and manufacturing capabilities.
Despite the general support, the discussions highlighted some concerns, particularly in the wake of OXB's recent trading updates which, according to some investors, failed to adequately reassure stakeholders amid fears of cash flow issues. One participant highlighted the "badly botched release" of information, emphasizing the need for management to clarify growth prospects and alleviate investor fears about financial stability. Overall, while there is a clear recognition of OXB's strengths in the cell and gene therapy space, particularly regarding market share gains, this contrasts with anxieties about future cash requirements and operational transparency, underscoring a pivotal moment as the company gears up for its upcoming financial results presentation.
Show more
Oxford Biomedica Plc (OXB) has announced its total voting rights as of February 28, 2025, amounting to 105,975,816 ordinary shares. This figure is significant for shareholders to determine their reporting obligations under the FCA's rules. There are no shares held in treasury, providing a complete transparency of the company's capital structure.
Additionally, OXB's Chief Financial Officer, Dr. Lucinda Crabtree, is set to participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 11, 2025. This event highlights OXB's commitment to engaging with investors and providing insights into its operations and strategic direction. A live webcast will be available on OXB's investor relations website, further enhancing accessibility for stakeholders interested in the company's developments in cell and gene therapy manufacturing.
Show more
Just a reminder that OXB are quite active on their LinkedIn page: |
Yes, the Duchy tomatoes told him it was true. |
Why the senior staff don't seem to be able to buy though Same logic the King has never denied the existence of UFO s so he must know there is some truth in it |
That's a great reminder of one of OXB's many current bow strings Taffy, but you maybe remember (from the 10 days of interims) that unless something unexpected happens with Monkeypox, the near-term upside is currently limited to manufacturing trial material for what will eventually be 2 large trials (universal covid + mpox which uses the same base and can be a combined vaccine). |
GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update |
"My honest opinion is that they are all embargoed for a reason unknown to us" |
Regarding no director buys - I think that the policy is that they should build a personal holding that is equivalent to an annual LTIP award. No idea what time frame that's over. |
By the way - I tried to send Harry an apology using a 'message' directly to him. But as he has me filtered/blocked, the message would not send. So he wouldn't have seen my post unless somebody forwarded it to him. Or he might have briefly unfiltered me to have a sneaky view, as he has admitted doing on the odd occasion. My apologies to all offended by my 'skirt'. |
You might have hit the nail on the head.If you haven't got a microscope and 'Doctor' before your name,you're really not worth bothering with! |
My thoughts too icejelly. A better thought than 'perhaps there is nothing yet worth betting on'. |
Could it be that the directors feel they have enough shares through their options? |
Gareth, |
I've just heard a rumour Dom that Welby will be the new host of MOTD and Lineker is going to become the new Archbishop of Canterbury. If true then our non-exec board dodged a couple of bullets there imho. |
HST, I have questioned, as you know what do our corporate brokers do for us publicly. Broker notes, price targets, bringing in new partners. I'm only a novice, perhaps there is more paddling beneath the water but I can't see it. Director buys, it's been months since we speculated why no director buys, there cannot be sensitive information which prevents director buys months before and significant signed off deal (can there?). |
Because nobody has told Frank that OXB has shareholders? |
Repeated more times than UKGold I know, but I think the random walk with the daily chart doesn't ever really mean anything on low volume. Something of a trend happening over a few days on better than normal daily volume then fair enough, but at the moment OXB is very quiet. |
Really funny to watch the britishbulls bot dealing system get in such a complete pickle this week over trading this share. Issued a sell order as price drifted back to 410, then needed to reverse it a day later when short sided so asked clients to move to cash and will no doubt move back to buy as share price drifts higher. LTBH can be somewhat less stressful (sometimes!).... |
Its going to be full steam ahead for US equities and all things crypto for a few days at least.As for the UK,Reeves budget and the threat of tariffs suggest a relatively drab performance by UK equities.Of course its worth noting that if, perchance,you were interested in getting involved in crypto,the FCA have decided,along with the European Union,that its downright unhealthy for your average punter to have anything to do with crypto.So US crypto ETFs are off limits,for example,to your average uk investor as a convenient means of sharing in this prospective Trump/Musk inspired bonanza.You can buy crypto through an exchange like Coinbase but its not a simple affair and involves an element of security risk.Why half the globe is permitted to run wild sampling a universe of investment opportunities while the other half suffer a 1984 Big Brother syndrome is not quite clear.There are self assigned parties out there who appear to believe that they know best and we need protecting from ourselves.Sorry to ramble off topic,its an age thing. |
The Trump victory seems to be influencing the investors into favouring certain parts of the market atm (e.g. BTC, US small cap) and I wonder what influence this has on the UK mid cap world especially with the recent budget influences to work through. |
Harry.....I've been quiet of late but I'm still here. Despite the threat of increased tariffs for goods manufactured in the U.K. or Europe, I still regard this share as being Trump neutral and thus far things appear to be developing nicely. Achieving sustainable profitability ASAP must be the key objective going forward: after that the general story should come more into play and plenty of influential people have eyes on here. Keep smiling Harry. |
I'm sure it's their own vector Phil and it seems to have done very little for Syncona this morning too. |
SJ, |
Do we think that is one of our clients Cousin? |
Type | Ordinary Share |
Share ISIN | GB00BDFBVT43 |
Sector | Medicinal Chems,botanicl Pds |
Bid Price | 316.50 |
Offer Price | 319.50 |
Open | |
Shares Traded | 0.00 |
Last Trade | 00:00:00 |
Low - High | - |
Turnover | 89.54M |
Profit | -184.16M |
EPS - Basic | -1.7380 |
PE Ratio | -1.82 |
Market Cap | 335.9M |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions